Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Study Overview
=================
Brief Summary
-----------------
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).

Detailed Description
-----------------
Several anticancer and supportive care drugs used in oncology have an impact on the cardiovascular and metabolic systems, leading to a wide range of cardiovascular and metabolic disorders and side effects. Those are poorly described, due to the evolution of the anticancer pharmacopeia, and recent recognition of these adverse events. This study will investigate the potential benefits of a specialized cardio-oncology check-up and follow-up in this context.

Official Title
-----------------
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Conditions
-----------------
Cardiac Complication, Cardiovascular Complication, Cardiovascular Insufficiency, Oncologic Complications, Cardiac Insufficiency, Metabolic Disorder, Vascular Disorder, Cardiac Disorder

Intervention / Treatment
-----------------
* Drug: Anti-Cancer Agents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suffering a cancer Evaluated within a cardio-oncology program Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients having a benefit after this specific cardio-oncology check up and follow up |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating the overall survival of patients suffering from cardiovascular or metabolic side effect of oncology treatments |  | 5 years | 
| All relevants staisticals associations between adverse events and anticancer drugs |  | 5 years | 
| All relevant statistical associations between cardiovascular toxicities, and anticancer drugs |  | 5 years | 
| All relevants statistical associations between cardiovascular side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments |  | 5 years | 
| All relevant statistical associations between duration and type of treatement used to manage cardiovascular side effects induced by oncology treatments, and overall survival |  | 5 years | 
| All relevants statistical associations between differential features of subgroups of patients, and the occurence of cardiovascular side effects induced by oncology treatments |  | 5 years | 
| All relevant statistical associations between new therapies to treat or prevent the cardiovascular side effects induced by oncology treatments, and overall survival |  | 5 years | 
| All relevant statistical associations between the pre therapeutic cardiovascular checkup and follow up for patients with cancer or history of cancer, and the occurence of cardiovascular toxicities of oncology treatments. |  | 5 years | 
| All relevant statistical associations between metabolic toxicities, and anticancer drugs |  | 5 years | 
| All relevants statistical associations between metabolic side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments |  | 5 years | 
| All relevant statistical associations between duration and type of treatement used to manage metabolic side effects induced by oncology treatments, and overall survival |  | 5 years | 
| All relevants statistical associations between differential features of subgroups of patients, and the occurence of metabloic side effects induced by oncology treatments |  | 5 years | 
| All relevant statistical associations between new therapies to treat or prevent the metabolic side effects induced by oncology treatments, and overall survival |  | 5 years | 
| All relevant statistical associations between the pre therapeutic metabolic checkup and follow up for patients with cancer or history of cancer, and the occurence of metabolic toxicities of oncology treatments. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular prevention, anticancer drugs, cardiac toxicities, vascular toxicities, metabolic toxicities, adverse drug reactions